Conclusions: The real-world data highlight SGLT-2 inhibitors as promising for HF prevention and broader cardiometabolic health in T2DM, with potential value in managing complex comorbid profiles. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.